呼和浩特肛周脓肿的检查呼和浩特市治疗外痔较好的方法,呼市哪家医院痔疮治得好,如何治疗痔疮呼市,治便秘呼市哪个地方好,呼和浩特治疗痔疮怎么样,呼和浩特外痔疮有什么症状,痔疮呼和浩特医院

BEIJING, Dec. 10 (Xinhua) -- Pharmaceutical producers will risk having their operation license revoked if they use prohibited chemicals as medicine ingredients or involved in fake drug production, China's drug regulator said in a circular Saturday.The State Food and Drug Administration said it would name and shame pharmaceutical companies if they make phoney medicine and withdraw the operation licenses of pharmacies if they intentionally sell unqualified drugs.The circular came in the wake of several counterfeit medicine scandals uncovered by Chinese police in the past few months.On Nov. 4, police seized more than 65 million imitation medicinal tablets and arrested 114 suspects in a cross-provincial raid on counterfeit drugs.In October, police raided on an illegal drug production and sale network and ended up with the seizure of 190 million yuan (29.9 million U.S. dollars) worth of counterfeit drugs.The suspects were found to have used starch or corn powder as ingredients for bogus medicine, or re-packaged expired pharmaceuticals.Police also found animal feed and chemical pigments in the counterfeit products.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.

BEIJING, Oct. 13 (Xinhuanet) -- A new study finds that ginger may decrease the risk of colon cancer through diminishing the inflammation in the gut, according to media reports Thursday.Prior researches have found that chronicle inflammation in the gut is related to colon cancer, suggesting easing inflammation in intestines might reduce the risk of the cancer, said Suzanna M. Zick, lead author of the study published online in Cancer Prevention Research. Zick, also a naturopathic physician and research associate professor at University of Michigan Medical Center, and her colleagues, assigned 30 volunteers to take pills containing two grams of either placebo powder or ginger root extract, equivalent to about two tablespoons of ground-up raw ginger root.And they recorded the inflammations in the participants' intestines before and after the test period.The researchers found that participants taking ginger pills had 28 percent less inflammation in their intestines after the test. But no difference was found in those who took placebo.The findings are promising, but the researchers are not yet recommending people start taking more ginger at meal times. The study only involved 30 participants, so it is just a preliminary study. Zick said they hope to launch a larger study in the future, according to USA Today.

BEIJING, Jan. 8 (Xinhua) -- China's central authorities have highlighted travel safety as the nation on Sunday officially kicked off the world's largest holiday migration, a time in which mass numbers of passengers will be homeward bound for the traditional Chinese Spring Festival.Safe travel has emerged as a hot-button issue facing the government as passenger trips during the 40-day travel peak are expected to hit a record high of over 3 billion.Liu Tienan, vice chief of the National Development and Reform Commission, the country's top economic planner, told the press on Sunday that passenger transport during the period is not looking good as the enormous migration outweighs existing transportation capacities.?A volunteer guides passengers to their train at Chengdu Railway Station in Chengdu, capital of southwest China's Sichuan Province, Jan. 7, 2012. Starting from Jan. 8, 2012, China's transport system will undergo a 40-day travel rush, which is characterized by a hightened passenger flow around the time of the oncoming Chinese New Year.Liu warned of the likelihood of heavy snow and icy rain that could hamper travel while vowing greater efforts to avoid another travel disaster, as was seen in early 2008 when unprecedented heavy snow and freezing rain inundated the south of the country, bringing traffic to a standstill during the peak holiday season.A total of 3.16 billion passenger trips are expected during the next 40 days, up 9.1 percent from a year earlier, of which, 235 million trips will be made via the country's railways, up 6.1 percent year-on-year.Hu Yadong, vice minister of railways, said a daily average of 5.88 million people will make train trips during the period, 340,000 more than the corresponding period in 2011.At the Beijing Railway Station on Sunday, staff members checked passengers' train tickets and ID cards, as an ID-based train ticket purchasing system kicked off nationwide at the start of the new year in an effort to curb ticket scalping.

WASHINGTON, Nov. 7 (Xinhua) -- U.S. researchers have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.The findings, published Monday in the online edition of the Journal of Clinical Investigation, suggest that drugs targeting the brain and central nervous system could be a novel approach to treating diabetes."The brain is the body's only organ that needs a constant supply of glucose to survive, so it makes sense that it would have some say over how much glucose is produced," said study leader Meredith Hawkins, professor of medicine and director of the Global Diabetes Initiative at Yeshiva University, in a statement. "This role for the brain was demonstrated in earlier studies in rodents, but there was considerable controversy over whether the results could be applied to humans. We hope this study helps to settle the matter."In an earlier study in rodents, researchers showed that activation of potassium channels in the brain's hypothalamus sends signals to the liver that dampen its production of glucose. Those findings, published in Nature in 2005, challenged the conventional thinking that blood sugar production by the liver (the body's glucose factory) is regulated only by the pancreas (which makes insulin to metabolize glucose). But carefully performed studies on dogs, conducted at Vanderbilt University, failed to replicate the results, suggesting the Einstein findings in rodents might not be relevant to higher mammals, including humans.The current study, involving people, was aimed at resolving this controversy. Ten nondiabetic subjects were given oral diazoxide, a drug that activates potassium channels in the hypothalamus. (The drug is not used to treat diabetes.) Hormone secretion by the pancreas was controlled to ensure that any change in sugar production would only have occurred through the drug's effect on the brain. After the researchers administered the drug, blood tests revealed that patients' livers were producing significantly less glucose than before.Hawkins and her team then repeated this in rats, again giving diazoxide orally, achieving similar results. They confirmed that sufficient amounts of diazoxide crossed the blood-brain barrier to affect potassium channels in the hypothalamus. Additional experiments confirmed that diazoxide was working through the brain. Specifically, the researchers were able to completely block the effects of diazoxide by infusing a specific potassium channel blocker directly into the brain."This study confirms that the brain plays a significant role in regulating glucose production by the liver," said lead author Preeti Kishore, assistant professor of medicine. "We are now investigating whether this 'brain-to-liver' pathway is impaired in people with diabetes. If so, we may be able to restore normal glucose regulation by targeting potassium channels in the brain."